top of page
Medical Checkup

IMAGINE

Trial Enrolment Status

OPEN

Disease Under Study

Asthma

Duration

~64 weeks

About the Trial

Depemokimab Asthma Imaging and Bronchoscopy Sub-Study: Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably. The purpose of this study is to assess how depemokimab, a monoclonal antibody, affects the structure and function of the lungs in asthmatic participants with type 2 inflammation, characterized by an eosinophilic phenotype.

Mechanism of Action:

Long anti IL-5

Duration of Study

~64 weeks

Phase

III

Principal Investigator

Dr. George Philteos

Sub-Investigator

Dr. Anushya Chelvanathan

Study Coordinator

Kesana Vijeyaratnam

Durham Institute of Respirology | Dynamic Drug Advancement Ltd

Address:

Hours:

601 Harwood Avenue South, Suite 201

Ajax, Ontario L1S 2J5

M-F:

9:00am - 5:00pm

Closed on statutory holidays

Main Office Phone: 

 

 

​

Main Office Fax:   

Clinical Trial Phone:

Clinical Trial Fax: 

Dr. Chelvanathan: (905) 239 0225

Dr. Franco: (905) 239 0221

Dr. O'Loghlen: (905) 239 0221

Dr. Philteos: (905) 427 1419

(905) 427-0346

(365) 885-9086

(905) 239-0056

©2022 by Dynamic Drug Advancement. Proudly created with Wix.com

bottom of page